MANCHESTER, UK, April 04, 2021 (GLOBE NEWSWIRE) -- As concern around the health risks of alcohol-based sanitiser grows, more hospitals are switching to a safer alternative – HOCL (Hypochlorous Acid), produced by SpectrumX.
Hospitals have generally used alcohol-based sanitiser to prevent the spread of disease. But is the end of the line approaching for our go-to disinfectants? With other, better products on the rise, the future of alcohol sanitisers appears more and more sterile.
Of course, alcohol-based solutions do their job — they kill pathogens. But they're no longer the safest or most effective option on the market.
Commonly-used alcohol sanitisers can damage skin and trigger dermatitis, eczema, and psoriasis — all of which can be a living nightmare for ever-disinfecting medical staff. They’re also toxic, posing a risk to small children who might drink them.
Just to add fuel to the fire, they’re flammable too — enough to be identified by the NHS as a fire risk when left in hot cars!
With these drawbacks becoming more and more well-known, safer alternatives like HOCL are increasingly sought out by medical institutions and commercial clients. Luckily, SpectrumX – an HOCL provider based in the UK – are aiming to step into the breach, with their unique Spectricept solution.
Spectricept is completely safe for human use, yet 300 times more effective than bleach at killing pathogens (including bacteria and viruses – yes, even COVID-19).
It’s the only effective formulation of HOCL ever created for use in ‘real world’ conditions — and SpectrumX holds the license for the UK and Europe.
After a year on the frontlines against COVID-19, the prospect of switching to a safer, skin-friendly disinfectant has been warmly welcomed by medical staff.
Consultant Surgeon Dr Gordon Buchanan vouches for HOCL:
“My hands are my most important tool for my job. I believe we should be transitioning away from alcohol-based sanitisers in high-use environments.”
Dr Gary Davies, Medical Director at Chelsea & Westminster Hospital (where Spectricept is currently used), agrees:
“At the start of the pandemic, hand washing and hand sanitisers suddenly became even more important in the drive of preventing and limiting infection, but I don’t think we necessarily imagined we would be using sanitisers so intensively and for such a long period. Over time we have seen a really significant increase in skin conditions suffered by our staff from high usage of alcohol-based sanitisers. We proactively looked for a safe and effective solution to try to prevent this from happening and have now started utilising an HOCL based product produced by SpectrumX. Feedback from staff members has been overwhelmingly positive."
Whilst HOCL has important uses in the current pandemic scenario, it’s future applications have monumental potential effects for post-pandemic life. It’s clear that living in a post-pandemic world means embracing a greater level of sanitation in public spaces, the workplace and beyond. SpectrumX are currently supporting the Medical University Hospital Innsbruck who are leading a Phase 2 clinical trial for nebulised treatment of COVID-19 patients using SPC-069. SPC-069 is a new class of HOCL-based therapy designed to treat viral bacterial and fungal infections in the lung and respiratory tract. With the benefit of successful trial data, several other potential infection treatment possibilities will be investigated. These include: pneumonia, bronchitis, asthma, flu & the common cold. With advancing licenses for the only patent-protectable formulation of HOCL in the world, SpectrumX is set to radically alter the way humans treat infectious disease.
SpectrumX is currently raising capital prior to its 2021 listing on the London stock exchange. They intend to become a household name with their array of applications. If you would like to learn more about SpectrumX and how they will revolutionise traditional medicine please click here
CONTACT: Media contact - E-mail - email@example.com Company - SpectrumX Holdings Limited